Biocon Biologics to acquire Viatris’ Biosimilars assets for up to USD3.335bn
Goodwin’s London Life Sciences and New York M&A teams have advised Biocon Biologics Ltd in its agreement to acquire Viatris Inc’s global biosimilars business to create a fully integrated global biosimilars enterprise.